Get all premium features to the best stock analysis tool

Finranks

Finranks

Company

  • About us

Contact us

  • [email protected]

Follow us

  • Instagram
  • Telegram
  • LinkedIn

All rights reserved.

Privacy PolicyTerms of Conditions
  • Home
  • Markets
  • Screener
  • News
  • About
  1. Home
  3. CYRX
C

Cryoport, Inc. (CYRX)

NCM – Real Time Price. Currency in USD

7.82

-0.39 (-4.75%)

At close: Mar 27, 2026, 4:00 PM EDT

7.85

+0.03 (0.36%)

After-hours: Mar 27, 2026, 5:10 PM EDT

  • Summary
  • News
  • Chart
  • Financial
  • Dividends
  • Forecast
  • Ownership
  • Profile
Cryoport, Inc. (CYRX) Q4 2025 Earnings Call Transcript
04.03.2026

Cryoport, Inc. (CYRX) Q4 2025 Earnings Call Transcript

Cryoport, Inc. (CYRX) Q4 2025 Earnings Call Transcript

CryoPort, Inc. (CYRX) Reports Q4 Loss, Tops Revenue Estimates
03.03.2026

CryoPort, Inc. (CYRX) Reports Q4 Loss, Tops Revenue Estimates

CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.42 per share a year ago.

Cryoport Reports Fourth Quarter and Full-Year 2025 Financial Results
03.03.2026

Cryoport Reports Fourth Quarter and Full-Year 2025 Financial Results

FY 2025 revenue increased to $176.2 million, exceeding the high end of previous guidance Life Sciences Services revenue grew 18% year-over-year in FY 2025, including a 22% rise in BioStorage/BioServices revenue Commercial cell and gene therapy revenue increased 29% year-over-year to $33.4 million in FY 2025 Supported a record 760 global clinical trials and 20 commercially approved therapies as of December 31, 2025 Full-year 2026 revenue guidance of $190 million to $194 million (8%-10% growth y-o-y) NASHVILLE, Tenn., March 3, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced financial results for its fourth quarter (Q4) and year ended (FY) December 31, 2025.

Cryoport to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026
17.02.2026

Cryoport to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026

NASHVILLE, Tenn., Feb. 17, 2026 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of temperature-controlled supply chain solutions for the life sciences, today announced that the Company will report financial results for the fourth quarter and year ended December 31, 2025 on Tuesday, March 3, 2026 after U.S. markets close.

Cryoport's MVE Biological Solutions Introduces New Fusion® 800 Series
11.02.2026

Cryoport's MVE Biological Solutions Introduces New Fusion® 800 Series

Self-Sustaining Fusion® 800 Series  Cryogenic Freezer Delivers High-Capacity Storage, Flexibility, and Cost Benefits in Limited Space Environments NASHVILLE, Tenn., Feb. 11, 2026 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of temperature-controlled supply chain solutions for the life sciences, today announced the launch of the MVE Fusion® 800 Series, the next evolution of MVE Biological Solutions' patented, award-winning Fusion technology.

Cryoport: Picks And Shovels For The Gene Therapy Boom
02.12.2025

Cryoport: Picks And Shovels For The Gene Therapy Boom

Cryoport, Inc. (CYRX) is the leading provider of temperature-controlled supply chain solutions for the rapidly growing cell and gene therapy industry. CYRX supports 745 clinical trials and 19 commercial therapies, with commercial segment revenue up 36% YoY, reflecting accelerating industry adoption. Despite strong growth and a dominant market position, CYRX trades at depressed valuations, offering a deep value opportunity for patient investors.

Cryoport Systems Wins 2025 BioTech Breakthrough Award For “BioServices Innovation of the Year”
06.11.2025

Cryoport Systems Wins 2025 BioTech Breakthrough Award For “BioServices Innovation of the Year”

Annual Awards Program Recognizes Breakthrough Life Sciences & Biotechnology Innovation Around the World Annual Awards Program Recognizes Breakthrough Life Sciences & Biotechnology Innovation Around the World

Videos

No Data

There is no data to display

Press releases

Cryoport Reports Fourth Quarter and Full-Year 2025 Financial Results
03.03.2026

Cryoport Reports Fourth Quarter and Full-Year 2025 Financial Results

FY 2025 revenue increased to $176.2 million, exceeding the high end of previous guidance Life Sciences Services revenue grew 18% year-over-year in FY 2025, including a 22% rise in BioStorage/BioServices revenue Commercial cell and gene therapy revenue increased 29% year-over-year to $33.4 million in FY 2025 Supported a record 760 global clinical trials and 20 commercially approved therapies as of December 31, 2025 Full-year 2026 revenue guidance of $190 million to $194 million (8%-10% growth y-o-y) NASHVILLE, Tenn., March 3, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced financial results for its fourth quarter (Q4) and year ended (FY) December 31, 2025.

Cryoport's MVE Biological Solutions Introduces New Fusion® 800 Series
11.02.2026

Cryoport's MVE Biological Solutions Introduces New Fusion® 800 Series

Self-Sustaining Fusion® 800 Series  Cryogenic Freezer Delivers High-Capacity Storage, Flexibility, and Cost Benefits in Limited Space Environments NASHVILLE, Tenn., Feb. 11, 2026 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of temperature-controlled supply chain solutions for the life sciences, today announced the launch of the MVE Fusion® 800 Series, the next evolution of MVE Biological Solutions' patented, award-winning Fusion technology.

Cryoport Systems Wins 2025 BioTech Breakthrough Award For “BioServices Innovation of the Year”
06.11.2025

Cryoport Systems Wins 2025 BioTech Breakthrough Award For “BioServices Innovation of the Year”

Annual Awards Program Recognizes Breakthrough Life Sciences & Biotechnology Innovation Around the World Annual Awards Program Recognizes Breakthrough Life Sciences & Biotechnology Innovation Around the World

Cryoport Reports Third Quarter 2025 Financial Results
04.11.2025

Cryoport Reports Third Quarter 2025 Financial Results

Third quarter revenue increased 15% year-over-year to $44.2 million Commercial Cell & Gene Therapy revenue increased 36% year-over-year to $8.3 million Life Sciences Services revenue grew 16% year-over-year, including a 21% rise in BioStorage/BioServices revenue Life Sciences Products revenue grew 15% year-over-year Company updates full year 2025 revenue guidance of $170 to $174 million NASHVILLE, Tenn. , Nov. 4, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of temperature-controlled supply chain solutions for the life sciences, today announced financial results for its third quarter (Q3) and first nine months (9M) of 2025.